Success Story

Cabaletta Bio expands Penn partnership

Cabaletta Bio, a gene therapy company focused on autoimmune diseases, expanded its sponsored research agreement with Penn this year to include three additional B cell-mediated autoimmune disease targets. The research is being conducted under the direction of Cabaletta co-founder Aimee Payne, PhD, an Associate Professor of Dermatology in Penn’s Perelman School of Medicine and director of the Penn Clinical Autoimmunity Center of Excellence.

Aimee S. Payne, MD, PhD (Center)

Skip to content